Akorn Announces Launch Of Myorisan, 30mg - QUick Facts

(RTTNews) - Specialty pharmaceutical company Akorn, Inc. (AKRX) Monday announced the launch of the recently-approved 30 mg strength of Myorisan, which is indicated for the treatment of severe recalcitrant nodular acne. This launch, the company noted, further builds the Myorisan product portfolio that also includes 10 mg, 20 mg and 40 mg capsules.

Myorisan (isotretinoin capsules, USP) in 10 mg, 20 mg, 30 mg and 40 mg strengths are marketed under the VersaPharm label. According to IMS Health, sales of 10 mg, 20 mg and 40 mg isotretinoin capsules were about $436 million for the year 2015, while sales of the 30 mg strength totaled about $209 million over the same period.